3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Hepatocellular
2
Ovarian Neoplasms
1
Neoplasms
1
Heart Failure
1
Endometrial Neoplasms
1
Endometrial Hyperplasia
1
Cardiotoxicity
1
Breast Neoplasms
1
Interventions
Doxorubicin
8
Cyclophosphamide
4
Docetaxel
3
Atorvastatin
3
dapagliflozin
2
Trastuzumab
2
Chemotherapy, Adjuvant
2
Carvedilol
2
nicotinamide-beta-riboside
1
empagliflozin
1
Tablets
1
Reverse Transcriptase Polymerase Chain Reaction
1
Radiotherapy
1
Paclitaxel
1
Neoadjuvant Therapy
1
Methotrexate
1
Metformin
1
Mass Spectrometry
1
Lisinopril
1
Leucovorin
1
Lapatinib
1
Hydroxymethylglutaryl-CoA Reductase Inhibitors
1
Gene Expression Profiling
1
Fluorophotometry
1
Filgrastim
1
Fenofibrate
1
Epirubicin
1
Environmental Biomarkers
1
Echocardiography
1
Dexrazoxane
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Cardiotoxicity
×
Hydroxymethylglutaryl-CoA Reductase Inhibitors
×
Clear all
NCT03186404
2022-02-08
SPARE-HF
University Health Network, Toronto
Phase 2
Unknown
112 enrolled